Long-term inhaled treprostinil for PH-ILD: INCREASE open-label extension study.

Aaron B WaxmanRicardo Restrepo-JaramilloThenappan ThenappanPeter EngelAbubakr BajwaAshwin RavichandranJeremy FeldmanAmy Hajari CaseVictor TapsonPeter SmithChunqin DengEric ShenSteven D Nathan

Published in: The European respiratory journal (2023)

These results support the long-term safety and efficacy of inhaled treprostinil in patients with PH-ILD and are consistent with the results observed in the INCREASE RCT.

Keyphrases

interstitial lung disease
open label
pulmonary arterial hypertension
cystic fibrosis
systemic sclerosis
clinical trial
phase ii
squamous cell carcinoma
randomized controlled trial
phase iii
locally advanced